A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 601–700 of 1,138
Portal pressure is of significant prognostic value in primary biliary cholangitis
Warnes, T. W., Roberts, S. A., Smith, A., Cope, V. M., Vales, P., & McMahon, R. F. (2022) · Liver International · doi:10.1111/liv.15289 · Cited by 11
Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis
Shah, R., & Kowdley, K. V. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679918 · Cited by 11
Self-citationUpdate on Emerging Treatment Options for Primary Biliary Cholangitis
Aguilar, M. T., & Chascsa, D. M. H. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s205431 · Cited by 11
Yang, Y., Yuan, W., He, K., Lin, C., Du, S., Kou, Y., & Nie, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1366479 · Cited by 13
“The FDA and the EU recently approved obeticholic acid (OCA), a potent FXR agonist, to treat primary biliary cholangitis (Nevens et al., 2016).”
BackgroundKomori, A., & Kugiyama, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0821 · Cited by 14
What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Wong, L. L., Hegade, V. S., & Jones, D. E. (2017) · Digestive Diseases · doi:10.1159/000467547 · Cited by 11
Self-citationFat malabsorption in short bowel syndrome: A review of pathophysiology and management
Hirsch, T. I., Wang, S. Z., Fligor, S. C., Quigley, M., Gura, K. M., Puder, M., & Tsikis, S. T. (2024) · Nutrition in Clinical Practice · doi:10.1002/ncp.11119 · Cited by 21
Current and emerging therapies for alcohol-associated hepatitis
Idalsoaga, F. J., Ayares, G., Díaz, L. A., Arnold, J., Ayala-Valverde, M., Hudson, D., Arrese, M. A., & Arab, J. P. (2023) · Liver Research · doi:10.1016/j.livres.2023.03.002 · Cited by 15
Wang, M.-N., Yu, H., Li, Y., Zeng, Y., Yang, S. C., Yang, G., Pei, Q., & Huang, J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s289016 · Cited by 11
Kunst, R. F., Bolt, I., van Dasselaar, R. D. J., Nijmeijer, B. A., Beuers, U. H., Elferink, R. P. J. O., & van de Graaf, S. F. J. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100917 · Cited by 14
Self-citationGao, Y., Li, L., Li, B., & Zhan, Y. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8829510 · Cited by 11
Hai, L., Wu, J., Pan, X., Yin, W., & Wu, Z. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70084 · Cited by 11
“Notably, patients undergoing OCA therapy experienced exacerbated pruritus in correlation with increased dosing [13, 29].”
Tian, S., Liu, Y., Sun, K., Zhou, X., Ma, S., Zhang, M., Zhou, X., Wang, L., & Han, Y. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23501 · Cited by 10
Precision medicine in primary sclerosing cholangitis
Maurice, J. B., & Thorburn, D. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12788 · Cited by 11
Chen, J., Xue, D., Gao, F., Tao, L., Li, Y., Zhang, Q., Wang, R., Sun, L., Yang, X. F., Liu, Y., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001186 · Cited by 10
Hayashi, M., Abe, K., Fujita, M., Okai, K., Takahashi, A., & Ohira, H. (2018) · Hepatology Research · doi:10.1111/hepr.13291 · Cited by 11
The treatment of primary biliary cholangitis: from shadow to light
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., & Jarčuška, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241265782 · Cited by 16
“The Japanese authors studied 150 antimitochon-drial antibody-positive PBC patients who did not respond to UDCA monotherapy and were treated”
BackgroundFreer, A., Williams, F. R., Durman, S., Hayden, J. K., Armstrong, M. J., & Trivedi, P. J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101210 · Cited by 24
Wang, Y., Zheng, L., Zhou, Z., Yao, D., Huang, Y., Liu, B., Duan, Y., & Li, Y. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16676 · Cited by 12
Prognostic models and autoimmune liver diseases
D’Amato, D., & Carbone, M. (2023) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2023.101878 · Cited by 10
Primary Biliary Cholangitis Guidance Update: Implications for Liver Transplantation
Levy, C. (2018) · Liver Transplantation · doi:10.1002/lt.25321 · Cited by 9
Implications of gut microbiota in autoimmune liver diseases
Qian, Q., He, W., Tang, R., & Ma, X. (2021) · Minerva Gastroenterology · doi:10.23736/s2724-5985.21.02860-9 · Cited by 11
Computational Insight into the Allosteric Activation Mechanism of Farnesoid X Receptor
Chen, Y., Li, J., Wu, Z., Liu, G., Li, H., Tang, Y., & Li, W. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00914 · Cited by 9
Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments
Gabrielli, F., Crepaldi, E., Cavicchioli, A., Rivi, M., Costanzo, A. A. C., Cursaro, C., & Andreoné, P. (2024) · Biomolecules · doi:10.3390/biom14101227 · Cited by 12
“However, the mechanism leading to the genesis of itching in this case has not yet been demonstrated [30–32].”
BackgroundSelf-citationNovel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis
Fuchs, C. D., Halilbasic, E., & Trauner, M. (2017) · Clinical Liver Disease · doi:10.1002/cld.613 · Cited by 9
Self-citationFuture Medical Treatment of PSC
Krones, E., Marschall, H., & Fickert, P. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00454-4 · Cited by 10
Self-citationEmerging Therapies for Alcoholic Hepatitis
Han, M. A. T., & Pyrsopoulos, N. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.03.006 · Cited by 9
The latest research trends in primary biliary cholangitis: a bibliometric analysis
Zhao, Y., Yin, Z., Du, H., Huang, K., Zhang, F., & Chen, H. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00825-0 · Cited by 9
“Two RCTs, one on obeticholic acid (OCA) [17] and the other on bezafibrate [18], were published in top journals (NEJM) and generated high citation rates.”
BackgroundRisk Stratification in Primary Biliary Cholangitis
Martini, F., Balducci, D., Mancinelli, M., Buzzanca, V., Fracchia, E., Tarantino, G., Benedetti, A., Marzioni, M., & Maroni, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175713 · Cited by 14
“For these patients, second-line therapies such as obeticholic acid (OCA) have been recently approved [7], and several other drugs are currently in clinical trials.”
BackgroundAdorini, L., Rigbolt, K. T. G., Feigh, M., Roth, J. D., & Erickson, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300809 · Cited by 10
Obeticholic acid as a second‐line treatment for low phospholipid‐associated cholelithiasis syndrome
Soret, P., Lemoinne, S., Mallet, M., Belkacem, K. B., Chazouillères, O., & Corpechot, C. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17761 · Cited by 10
“10 One explanation could be the very low level of cholestasis and cholangitis associated with LPAC syndrome.”
BackgroundPrecision medicine in primary biliary cholangitis
Ronca, V., Gerussi, A., Cristoferi, L., Carbone, M., & Invernizzi, P. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12787 · Cited by 9
Self-citationFallon, C. M., Smyth, J. S., Quach, A., Lajczak, N., O’Toole, A., Barrett, K. E., Sheridan, H., & Keely, S. J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102569 · Cited by 9
“Although identified as a receptor for BAs more than 20 years ago, development of selective agonists for FXR has been slow, with just one semi-synthetic ligand of the receptor, obeticholic acid (OCA, 6-ethyl-CDCA), having been approved for clinical use to treat primary biliary cholangitis (18).”
BackgroundXiong, A., Lu, L., Jiang, K., Wang, X., Chen, Y., Wang, X., Zhang, W., Zhuge, Y., Huang, W., Li, L., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03762-x · Cited by 11
“OCA is a known FXR agonist (Pellicciari et al. 2002) and is FDA-approved for treatment of primary biliary cholangitis patients not responding or intolerant to UDCA (Nevens et al. 2016).”
Selective Photoaffinity Probe for Monitoring Farnesoid X Receptor Expression in Cultured Cells
Xu, X., Zhu, Y., Song, J.-Z., Zou, G., Hao, H., Zheng, Q., Cao, L., Wang, G., Wang, H., & Hao, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01206 · Cited by 9
The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.
Cariello, M., Gadaleta, R. M., & Moschetta, A. (2022) · PubMed Central · doi:10.1097/mog.0000000000000807 · Cited by 4
“Different clinical trials have been performed, and it has been shown that UDCA may slow down PSC progression at some level; however, a real clinical effectiveness has yet to be demonstrated [84,85].”
BackgroundInfluentialTreatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Self-citationCholestatic liver diseases: modern therapeutics
McNally, B. B., & Carey, E. J. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2473490 · Cited by 11
“UDCA has been associated with a decreased need for liver transplantation [3,7,8].”
PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old
Tanaka, A., & Corpechot, C. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102358 · Cited by 9
Xue, C., Li, P., Xuan, M., Li, L., & Shi, Q. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156942 · Cited by 10
Xu, J. Y., Zhang, H., Chen, H., Zhu, X., Jia, H., Xu, Z., Huo, D., Zhang, H., Li, C., & Ding, Y. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2264850 · Cited by 9
“…and 68% in the placebo, 5 + 10 mg, and 10 mg cohorts, respectively. the severity of pruritus was lower in the titration cohort than in the 10 mg Oca cohort [25]. as mentioned above, we also chose the titration method in our study. the severity of pruritus was lower in the 0.2 + 0.5 + 1 mg group.”
MethodInfluentialPretransplant Evaluation and Liver Transplantation Outcome in PBC Patients
Mijić, M., Saric, I., Delija, B., Lalovac, M., Sobočan, N., Radetić, E., Martinčević, D., & Kanižaj, T. F. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/7831165 · Cited by 11
Sohal, A., & Kowdley, K. V. (2023) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s361077 · Cited by 9
“Pruritus is the most common side effect associated with OCA use.(60) The underlying mechanism of action for this symptom is unknown.”
BackgroundInfluentialSelf-citationEmerging Therapeutic Strategies in the Fight Against Primary Biliary Cholangitis
Medford, A., Childs, J. R., Little, A., Chakraborty, S., Baiocchi, L., Alpini, G. D., & Glaser, S. S. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00398 · Cited by 11
Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis
Shin, S., Moh, I. H., Woo, Y. S., Jung, S. W., Kim, J. B., Park, J. W., Suk, K. T., Kim, H. S., Hong, M., Park, S. H., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i39.7191 · Cited by 8
Gitto, S., Guarneri, V., Sartini, A., & Andreoné, P. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1399060 · Cited by 9
“parallel-group, 12-month phase 3 trial [25].”
MethodSelf-citationDing, D., Ren, P., Guo, G., Liu, Y., Yang, C., Zheng, L., Jia, G., Deng, J., Sun, R., Wang, X., et al. (2023) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.01.001 · Cited by 8
FXR Friend-ChIPs in the Enterohepatic System
Meadows, V., Yang, Z., Basaly, V., & Guo, G. L. (2023) · Seminars in Liver Disease · doi:10.1055/a-2128-5538 · Cited by 9
“Recent Advances of the FXR Proteome Utilization of global FXR agonists in primary biliary cholangitis and NASH patients remains controversial due to severe adverse effects such as pruritus, fatigue, and increased serum low density lipoprotein (123-125).”
BackgroundInvestigational drugs in early phase development for primary biliary cholangitis
Gochanour, E. M., & Kowdley, K. V. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1857364 · Cited by 9
Self-citationCorpechot, C., Hornus, P., Cals, M., Rinder, P., Marcille, T., Malek, A., Belkacem, K. B., Gaouar, F., Chabane, Y., Corret, P., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101546 · Cited by 11
Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
Floreani, A. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267375 · Cited by 9
Self-citationAdvancing Second-Line Treatment for Primary Biliary Cholangitis
Assis, D. N. (2024) · New England Journal of Medicine · doi:10.1056/nejme2312745 · Cited by 8
The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine
Men, X., Liu, Y., Zhao, H., Xie, B., Guo, C., Leung, P. S. C., Timilsina, S., Gershwin, M. E., Shang, Y., & Han, Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09074-x · Cited by 15
“In the phase-III POISE clinical trial, compared with the placebo group, the biochemical response rates were 36% ( p < 0.001, Relative Risk (RR) = 4.85; 95% CI, 2.3–10.23) and 37% ( p < 0.001, RR = 4.85; 95% CI, 2.3–10.23) higher in the OCA 5–10 mg and 10 mg groups, respectively [81, 88].”
InfluentialApproved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective
Zhu, J., Luo, G., & Xiang, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03005 · Cited by 10
Fu, X., Song, Y., Lin, J.-Y., Wang, Y., Wu, W., Peng, J., Ye, L., Chen, K., & Li, S.-W. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.88481 · Cited by 10
“PBC is a rare autoimmune liver disease characterized by inflammation and progressive destruction of interlobular bile ducts and biliary stasis causing debilitating fatigue and pruritus, ultimately leading to cirrhosis and death [17, 18].”
BackgroundPlasma lipidomics of primary biliary cholangitis and its comparison with Sjögren’s syndrome
Li, H., Zhan, H., Cheng, L., Huang, Y., Li, X., Yan, S., Liu, Y., Wang, L., & Li, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1124443 · Cited by 9
“Furthermore, we categorized these patients into two groups: UDCA responder (n = 20) and UDCA non-responder (n = 20), which were established using the POISE criteria (16) [ALP <1.”
MethodObeticholic acid in primary biliary cholangitis
Erlinger, S. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.09.006 · Cited by 9
Tsuji, K., Tamaki, N., Kurosaki, M., Mori, N., Takaki, S., Ohya, K., Mashiba, T., Ochi, H., Kobashi, H., Ogawa, C., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14172 · Cited by 8
“As there is no established treatment for patients with PBC who do not respondtoUDCAalone,bezafibratehasbeenusedempiricallyinJapan for more than 20 years, especially for early - stage PBC, and has been reported to reduce biliary liver enzymes and improve long - term prognosis in patients with PBC. 27,28 In Europe and t…”
InfluentialUse of Obeticholic Acid in Patients With Primary Biliary Cholangitis.
Brown, R. S. (2018) · Europe PMC (PubMed Central) · Cited by 9
Pharmacologic management of primary sclerosing cholangitis: what’s in the pipeline?
Suri, J. S., Patwardhan, V. R., & Bonder, A. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1636647 · Cited by 8
Patient ownership of primary biliary cholangitis long-term management
Leighton, J., Thain, C., Mitchell-Thain, R., Dyson, J. K., & Jones, D. E. J. (2020) · Frontline Gastroenterology · doi:10.1136/flgastro-2019-101324 · Cited by 8
Self-citationThe Discovery of Obeticholic Acid ( Ocaliva™ ): First‐in‐Class FXR Agonist
Pellicciari, R., Pruzanski, M., & Gioiello, A. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch8 · Cited by 12
Self-citationEvaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
Caines, A., Trudeau, S., & Gordon, S. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2390120 · Cited by 7
“Early studies reported that roughly 45% of patients treated with OCA will respond with a reduction in ALP to less than 1.67 times the upper limit of normal (ULN) and with normal total bilirubin (TB) [13].”
InfluentialHuang, L.-X., Wang, Z., Jin, R., Chen, H., & Feng, B. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2153672 · Cited by 14
Evolving role of obeticholic acid in primary biliary cholangitis
Levy, C. (2018) · Hepatology · doi:10.1002/hep.29726 · Cited by 7
“Following completion of a large international phase 3 study (The PBC OCA International Study of Efficacy; POISE), the U.S. Food and Drug Administration (FDA) granted conditional approval for OCA as second-line therapy in PBC, indicated in combination to UDCA for patients who had inadequate response after at least 1 ye…”
MethodInfluentialQuigley, G., Ani, M. A., & Nadir, A. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4900-8 · Cited by 7
“However, in the OCA registration trial that led to approval of this drug as both monotherapy and in combination with UDCA for PBC, only eleven subjects were placed on OCA monotherapy after discontinuing UDCA for 3 months, while 93% of subjects remained stable on UDCA therapy in combination with OCA throughout the tria…”
BackgroundResultInfluentialMitochondria at the Crossroads of Cholestatic Liver Injury: Targeting Novel Therapeutic Avenues
Li, X., Ruan, T., Wang, S., Sun, X., Liu, C., Yongjie, P. E. N. G., & Tao, Y.-Y. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00087 · Cited by 19
Novel Therapies in Primary Biliary Cholangitis
Buchanan-Peart, K.-A., & Levy, C. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.013 · Cited by 7
A historical review of jaundice: May the golden oriole live forever
Herta, T., & Beuers, U. H. (2022) · Clinical Liver Disease · doi:10.1002/cld.1267 · Cited by 8
Self-citationEvolving therapeutic landscape of primary biliary cholangitis: A review
Mitchell, N. E., Chan, S., Diaz, D. J., Ansari, N., Lee, J. S., & Twohig, P. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107223 · Cited by 11
Ayers, M., Liu, S., Singhi, A. D., Kosar, K., Cornuet, P. K., & Nejak‐Bowen, K. N. (2022) · Scientific Reports · doi:10.1038/s41598-021-04358-6 · Cited by 7
Zhao, J., Yue, P., Mi, N., Li, M., Fu, W., Zhang, X., Gao, L., Bai, M., Tian, L., Jiang, N., et al. (2024) · Medical Review · doi:10.1515/mr-2024-0029 · Cited by 11
“Clinical studies have shown that OCA combination therapy reduced the levels of ALP and bilirubin and improved long-term outcomes such as liver fi brosis stage, ductular reaction, and bile duct de fi ciency in the PBC patients with poor response to UDCA [400, 418, 419].”
BackgroundTranscriptional Control of Trpm6 by the Nuclear Receptor FXR
Kim, E. Y., & Lee, J. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041980 · Cited by 9
“Among them, obeticholic acid (OCA), a semisynthetic chenodeoxycholic aid (also known as 6α-ethyl-chenodeoxycholic acid or INT-747), is about 100-fold more potent than chenodeoxycholic acid (CDCA) and has been approved to treat primary biliary cholangitis despite pruritis as a side effect for some patients [34,35].”
BackgroundLi, W., Huang, D., Luo, Z., Zhou, T., & Jin, Z. (2025) · Pharmaceuticals · doi:10.3390/ph18070932 · Cited by 9
“Current first-line treatments, such as UDCA and OCA, fail to achieve adequate biochemical or histological responses in approximately 50% of patients [2,3].”
Kimura, N., Takahashi, K., Setsu, T., Horibata, Y., Kaneko, Y., Miyazaki, H., Ogawa, K., Kawata, Y., Sakai, N., Watanabe, Y., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13966 · Cited by 10
“Bezafibrate 7,8 and obeticholic acid 9 are beneficial for patients with PBC treated with UDCA.”
BackgroundPrimary biliary cholangitis: new treatments for an old disease
Trivedi, H. D., Lizaola‐Mayo, B., Tapper, E. B., & Bonder, A. (2016) · Frontline Gastroenterology · doi:10.1136/flgastro-2016-100741 · Cited by 7
Abbas, N., Smith, R. A., Lytvyak, E., Scraravaglio, M., Halliday, N., Almahroos, A., Eden, N., Lloyd‐Madden, D., Sharma, S., Ferguson, J., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70378 · Cited by 9
“…agonist, Obeticholic acid (OCA), gained market entry as a second-line therapy for PBC. Robustly conducted controlled trials showed that OCA treatment was associated with a reduction in serum alkaline phosphatase (ALP) values among patients with inadequate response (or intolerance) to UDCA [28–30].”
InfluentialSelf-citationManagement of primary biliary cholangitis prior to obeticholic acid availability
Durazzo, M., Bonetto, S., Fagoonee, S., Morgando, A., & Pellicano, R. (2018) · Minerva Medica · doi:10.23736/s0026-4806.18.05774-9 · Cited by 7
“The response to UCDA therapy was assessed comparing the parameters of our cohort with the inclusion criteria of the POISE trial 18 and with Paris I 19 and Paris II 20 criteria.”
Pathogenesis and management of fatigue in primary biliary cholangitis
Shamshtein, D., & Liwinski, T. (2022) · Fatigue Biomedicine Health & Behavior · doi:10.1080/21641846.2022.2034473 · Cited by 10
“Unfortunately, the current PBC first-line therapy ursodeoxycholic acid (UDCA) and second-line therapy obeticholic acid (OCA) are ineffective in improving PBC-related symptoms, which creates the need for additional therapeutic measures [7, 8].”
BackgroundAishwarya, T. S., Mounika, N., Vishwakarma, G., & Adela, R. (2022) · RPS Pharmacy and Pharmacology Reports · doi:10.1093/rpsppr/rqac001 · Cited by 8
Investigational drugs in phase II clinical trials for primary biliary cholangitis
Silveira, M. G., & Lindor, K. D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1371135 · Cited by 6
Self-citationBossen, L., Lau, T. S., Nielsen, M. B., Nielsen, M. C., Andersen, A. H., Ott, P., Becker, S., Glerup, H., Svenningsen, L., Eivindson, M., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000068 · Cited by 8
“67× the upper limit of normal (175 U/I) or abnormal bilirubin (> 25 μmol/L) after at least 1 year of UDCA treatment were considered incomplete responders to UDCA treatment as defined by the POISE criteria.[31] All biopsies in the cohort of incident PBC patients were staged according to the Ludwig system.”
MethodKowdley, K. V., Ieyoub, J., Pan, Y., Samnaliev, M., Ito, D., & Perez, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70391 · Cited by 9
“In comparison, in the POISE trial, only 9% of patients discontinued treatment [21, 23].”
Self-citationAntifibrotic therapies in liver disease: Ready for primetime?
Rudnick, D. A. (2017) · Clinical Liver Disease · doi:10.1002/cld.641 · Cited by 7
Yu, C., Han, D., Yu, J., Zhu, R., Zhu, C., Wang, F., & Zhang, T. (2023) · Medicine · doi:10.1097/md.0000000000035460 · Cited by 9
“[9] Saroglitazar, a novel PPAR α / γ agonist, has been approved for marketing in India as the first new NASH drug.”
BackgroundAli, J. S., Ali, T. S., & Hasibuzzaman, M. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002868 · Cited by 9
“Obeticholic acid, a selective farnesoid X receptor agonist, is approved as a second-line therapy; but less than 50% patients achieve a biochemical response, and it can aggravate pruritus [7] .”
Natural Product 2-Oxokolavenol Is a Novel FXR Agonist
Guo, F., Gao, Y., Li, X., & Lei, X. (2022) · Molecules · doi:10.3390/molecules27248968 · Cited by 8
“Collectively, the approval of OCA by the FDA for PBC treatment in the clinic confirms the reliability of FXR as a drug target for liver damage.”
BackgroundInfluentialNierath, W., Leitner, E., Reimann, S., Schwarz, R., Hinz, B., Bleich, A., Vollmar, B., & Zechner, D. (2024) · The FASEB Journal · doi:10.1096/fj.202400733r · Cited by 6
“20 So far no drugs have been approved for the treatment of PSC. 21 23 OCA demonstrates the potential to lower serum alkaline phosphatase (ALP) levels, but it also causes pruritus as a common side effect.”
Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies
Curto, A., Iamello, R. G., Lynch, E. N., & Galli, A. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i30.109028 · Cited by 6
The role of bile salts in itch receptor activation
Wolters, F., Tolenaars, D., van Weeghel, M., de Waart, D. R., van de Graaf, S. F. J., Paulusma, C. C., Verhoeven, A. J., Beuers, U. H., & Elferink, R. P. J. O. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167972 · Cited by 8
Self-citationAutorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
Future potential therapeutics to treat MASH
Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 10
Chen, J., Stringer, R. A., Shah, B., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1140 · Cited by 6
Tanaka, A., Leung, P. S. C., Young, H. A., & Gershwin, M. E. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.70995 · Cited by 7
AlWabel, A. H., Peedikayil, M. C., Alnasser, S. A., AlHusaini, K., Alhekail, O. Z. O., Alqahtani, S. A., Altraif, I., & Al-Ashgar, H. I. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_445_21 · Cited by 6
“It improves biochemical changes in PBC.[14,15] Besides the above treatments, fibrates in combination with UDCA were found beneficial in treating PBC patients with inadequate response to UDCA.”
BackgroundInfluentialKamrul-Hasan, A. B. M., Mondal, S., Nagendra, L., Sasikanth, T., Ahammed, A., Rahman, S. I., Wickramarachchi, A. W., Parajuli, N., Khatiwada, S., & Dutta, D. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.8 · Cited by 8
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
Levy, C. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.2709 · Cited by 7
Refat, M., Zhang, G., Saad, A. A. A., Baldi, S., Zheng, F., & Wu, X. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110331 · Cited by 6
Cytotoxic Effect of 6-Ethyl-Chenodeoxycholic Acid and Cabazitaxel on PC-3 Cells
Zalzala, M. H., Al-khfajy, W. S., & Khaleel, R. A. (2023) · Drug development & registration · doi:10.33380/2305-2066-2023-12-1-52-58 · Cited by 8
Li, T., & Jing, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1565778 · Cited by 8
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.